Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Overview
- Phase
- Phase 2
- Intervention
- Gilenya
- Conditions
- Amyotrophic Lateral Sclerosis
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 30
- Locations
- 4
- Primary Endpoint
- Forced Expiratory Volume in 1 Second (FEV1)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
Detailed Description
The primary objective of the study is to determine the acute safety and tolerability of oral administration of Gilenya (fingolimod) 0.5mg daily vs. matched oral placebo administered daily. The primary outcome measure will be safety and tolerability; safety will be assessed by the occurrence of adverse events and clinically meaningful changes in vital signs, ophthalmologic examination, physical examination, electrocardiogram and standard clinical laboratory blood tests, and tolerability will be defined as the ability of subjects to complete the entire 4-week study. The secondary outcome measure will be the measured effect of the treatment on circulating lymphocyte populations in patients with ALS. Exploratory outcome measures will include the rate of decline of the ALS Functional Rating Scale (Revised) (ALSFRS-R) and Slow Vital Capacity (VC) during the course of treatment. This study will be conducted in subjects who meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS. At screening, eligible subjects must be at least 18 years old, must have an SVC ≥ 65% of predicted capacity for age, height and gender, and must provide written informed consent prior to screening. Subjects on a stable dose of riluzole and those not taking riluzole, and women of child-bearing age at screening are eligible for inclusion as long as they meet specific protocol requirements. Subjects will remain on randomized, placebo-controlled, double-blind treatment until the Week 4 visit. Each randomized subject will also have a Week 8 Follow-up Telephone Interview to assess for adverse events (AEs), changes in concomitant medications and to administer the ALSFRS-R.
Investigators
James D. Berry MD
MGH Assistant Neurologist, HMS Instructor in Neurology
Massachusetts General Hospital
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older.
- •Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).
- •Onset of weakness or spasticity due to ALS ≤ 2 years (24 months) prior to Baseline Visit.
- •Slow vital capacity (SVC) measure ≥65% of predicted for gender, height, and age at the screening visit.
- •Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to randomization (riluzole-naïve subjects are permitted in the study).
- •Subjects must be able to swallow oral medication at the Screening Visit and expected to be able to swallow the capsule throughout the course of the study.
- •Capable of providing informed consent and following trial procedures.
- •Geographically accessible to the site.
- •Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.
- •Subjects must agree not to take live attenuated vaccines (including seasonal flu vaccine) 30 days before randomization, throughout the duration of the trial and for 60 days following the trial.
Exclusion Criteria
- •Prior use of fingolimod (Gilenya®).
- •History or presence of cardiac conditions including:
- •Cardiovascular or cerebrovascular disease in the previous 6 months (eg. myocardial infarction, unstable angina, or stroke)
- •Congestive heart failure
- •First, second- or third-degree atrioventricular block, sick sinus syndrome, or other serious cardiac rhythm disturbances
- •Any history of Torsades de Pointes
- •Treatment with a prohibited medication within 30 days of the Baseline Visit:
- •a. Class Ia or III antiarrhythmic medications: i.e., Quinidine, Sotalol Includes Nuedexta b. QT interval prolonging medications c. Ketoconazole d. Beta-blockers e. Calcium channel blockers f. Immunosuppressant medication g. Chemotherapeutic (anti-neoplastic) medications
- •Evidence on examination or ECG of bradycardia (\<55 bpm), QTc \>450ms for women or \>430 msec for men, or 1st degree or higher conduction block.
- •History of unexplained syncope or cardiac syncope.
Arms & Interventions
Gilenya (fingolimod)
0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
Intervention: Gilenya
Placebo
0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
Intervention: Placebo
Outcomes
Primary Outcomes
Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: Screening, Week 0, Week 2, and Week 4
Forced Expiratory Volume (FEV1): Forced Expiratory Volume (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.
ALSFRS-R Total Score at Weeks 0, 2, 4 and 8
Time Frame: Week 0, Week 2, Week 4 and Week 8
The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival.
Change in Slow Vital Capacity Score (SVC)
Time Frame: Week 0, Week 2, Week 4 and Week 8
The vital capacity (VC) (percent of predicted normal) was determined using the slow VC method. Vital Capacity is the maximum amount of air a person can expel from the lungs after a maximum inhalation. A subject's VC depends on their age, sex and height. The value is recorded as a percent of predicted normal.
Secondary Outcomes
- Forced Expiratory Volume in 1 Second (FEV1) / Slow Vital Capacity (SVC) Ratio(Screening, Week 0, Week 2, and Week 4)
- Lymphocyte (T-Cell) Subset Trajectories(Week 0, Week 2, and Week 4)